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Abstract 
 
PrediXcan is a recent software for the imputation of gene expression from genotype data alone. 
Using an overlapping set of transcriptome datasets from postmortem brain tissues of donors with 
alcohol use disorder and neurotypical controls, which were generated by two different platforms (e.g., 
Arraystar and Affymetrix), and an additional unrelated transcriptome dataset from lung tissue, we 
sought to evaluate PrediXcan’s ability to impute gene expression and identify differentially expressed 
genes. From the Arraystar platform, 1.3% of matched genes between the measured and imputed 
expression had a Pearson correlation ≥ 0.5. Our attempt to replicate this finding using the expression 
data from the Affymetrix platform also lead to a similarly poor outcome (2.7%). Our third attempt using 
the transcriptome data from lung tissue produced similar results (1.1%) but performance improved 
markedly after filtering out genes with a low predicted R2, which was a model metric provided by the 
PrediXcan authors. For example, filtering out genes with a predicted R2 below 0.6 led to 16 genes 
remaining and a Pearson correlation of 0.365 between the measured and imputed expression. We were 
unable to reproduce similar performance gains with filtering the Arraystar or Affymetrix alcohol use 
disorder datasets. Given that PrediXcan can impute a narrow portion of the transcriptome, which is 
further reduced significantly by filtering, we believe caution is warranted with the interpretation of 
results derived from PrediXcan.  
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Chapter 1 
Introduction 
 
 Assessing gene expression via high-throughput expression platforms is becoming an increasingly 
ubiquitous approach to study the molecular underpinnings underlying complex phenotype differences 
between clinical samples. In hybridization (i.e. microarray) experiments, RNA is reverse transcribed to 
copy DNA (cDNA), labeled with a fluorescent tag, and allowed to hybridize to complementary probes on 
a microarray platform; thus, the expression of a gene can be assessed by detecting the presence of the 
label at specific probe sites. As such platforms contain numerous probes, they are able to quantify the 
expression of tens of thousands of genes per sample, which make these platforms attractive for an 
unbiased assessment of gene expression patterns. However, microarray platforms can only detect the 
presence of known transcripts and are known for being sensitive to technical artefacts. For instance, one 
study found that between 50.5% to 82.8% of all probes, using either an Affymetrix or Agilent platform, 
correlated significantly with array batches (Leek, 2010). This sensitivity can be explained by seemingly 
minuscule factors, such as ozone levels that meet the Environmental Protection Agency’s standard for 
“good” air quality, having been shown to effect expression measurements (Byerly, 2009).  
 RNA-sequencing is another popular method to assess expression levels, which isn’t as sensitive 
to background noise (Su, 2014). By reverse transcribing the RNA sample to DNA, amplification via 
polymerase chain reaction, and then sequencing, RNA-sequencing is able to provide a more 
comprehensive measurement of the transcriptome, which also includes detection of alternative and 
unknown transcripts. Unfortunately, measuring differential expression of various phenotypes is 
hampered by small effect sizes caused by the reliance on clinical assessments, high genetic 
heterogeneity, and co-regulation of genes unrelated to the phenotype of interest. Additionally, RNA is 
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quite prone to degradation, which frequently leads to differential degradation among species of RNA 
(Garneau 2007; Ferrer 2008). Consequently, these factors add noise, which researchers often overcome 
with larger sample sizes. However, for psychiatric illnesses, where researchers are limited to post-
mortem samples, as the disease organ is the brain, procuring sufficient samples is fraught with difficulty 
and high costs.  
 One such psychiatric ailment is alcohol use disorder (AUD). As defined by the Diagnostic and 
Statistical Manual of Mental Disorders (5th ed.; DSM-5; American Psychiatric Association, 2013), AUD is 
measured by its severity (mild, moderate, or severe) based on the cumulative sum of eleven different 
symptoms; such symptoms include alcohol interfering with one’s job or family, being fixated on drinking 
alcohol, and drinking more in order to reach a desired effect. For Americans over the age of 18, the 
average rate of AUD was high for twelve-month (13.9%) and lifetime (29.1%) prevalence (Grant, 2015); 
when one considers white men, the rates for twelve-month (17.6%) and lifetime (36.0%) are even more 
despairing. Additionally, two meta-analyses of global epidemiology studies have estimated AUD relative 
risk for all-cause mortality for both sexes to be 3.45 (2.96-4.02) and 3.55 (2.48-5.09) (Laramee, 2015; 
Roerecke, 2013). Much of this can be explained by the numerous physical ailments strongly associated 
with alcoholism (e.g. liver cirrhosis, heart disease, etc). But despite the significant health effects, it is 
estimated that only 24.1% of those with alcohol dependency will receive treatment in their lifetime 
(Hasin, 2007). 
 Unfortunately, AUD treatment is limited as there are only 3 unique Food and Drug 
Administration approved agents for the treatment of alcohol abuse, with the last one being approved in 
2004 (Ray, 2018). Combinational treatments (therapy and pharmacological intervention) have shown 
efficacious results, but such treatments have failed a large portion of participants and the longevity of 
abstinence is questionable; for instance, one combinational trial (naltrexone, acamprosate, and 
cognitive behavioral therapy) reached an abstinence rate of 67% but only spanned 84 days (Feeney, 
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2006). Thus, when one considers alcohol abuse’s prevalence, mortality risk, and lack of pharmaceutical 
options, the necessity to find additional treatments becomes apparent. But because of the challenges 
face with differential expression, elucidating these complex psychiatric phenotypes has been 
challenging.  
 
1.1 PrediXcan 
PrediXcan is a recent software developed for predicting expression levels from genotype data alone 
(Gamazon, 2015). It accomplishes this by building upon the idea of an expression quantitative trait loci 
(eQTL) analysis, which finds associations between expression levels and single nucleotide 
polymorphisms (SNPs), which represents sites of genomic variability. But instead of using an ordinary 
least square regression to find such associations, PrediXcan utilizes an elastic net, which combines two 
penalizing regression methods. The first is ridge regression, which down weights correlated predictors 
and hence is able to account for linkage disequilibrium, which is the non-random association of alleles, 
without pruning/clumping highly correlated SNPs (Malo, 2008). The second is lasso regression, which 
uses shrinkage i.e., the values of nonmeaningful variables are shrunk towards a central point (usually the 
mean) and eventually eliminated from the model, creating a more parsimonious model (Waldmann, 
2013). But as lasso regression performs poorly in certain situations, such as with highly correlated 
variables, it does not necessarily perform better than ridge regression in performance (Zou, 2005). Thus, 
the elastic net model essentially amounts to a compromise between ridge regression and lasso 
regression.  
By utilizing elastic net methodology and a transcriptome dataset, which contain both genotype and 
expression data, the authors of PrediXcan have been able to ascribe weights to the genotype 
4 
 
components (i.e. SNPs), which corresponds to the expression of select genes. These weights have been 
made available by the authors, in the form of an SQLite file, to be used by PrediXcan. When a user runs 
PrediXcan with unrelated genotype data, PrediXcan will match SNPs in the unrelated genotype data to 
the weights in the SQLite file. And when matches are found, those weights will be used to add/subtract 
from the expression value of the corresponding gene of a given individual. In doing so, PrediXcan is able 
to impute gene expression from unrelated genotype data at the individual level.  
One of the most popular and comprehensive transcriptome datasets is the Genotype-Tissue 
Expression (GTEx) project, which aims to include the genotype and tissue specific expression of over 900 
deceased donors (The GTEx Consortium, 2013). Currently, version 7 is the most recent release of GTEx 
and incorporates the genotype and expression data from 635 donors. The authors of PrediXcan have 
taken this data, adjusted it to account for sex and experimental/population confounders, used the 
elastic net methodology to calculate the expression weights for the genotypic components, and made 
the SQLite weights files available on predictdb.org.  
Additionally, the authors utilized 10-fold cross-validation to derive quality measure for each gene 
model. With this procedure, a subset of expression data was extracted out, the elastic net was 
conducted, and the model’s imputed results was compared against the extracted expression. This step 
was repeated 9 more times and thus allowed the model to be evaluated using the same transcriptome 
dataset. From the cross-validation, several quality measures were calculated and provided in the GTEx 
version 7 SQLite weights files. One quality measure is “rho_avg”, which is the average Pearson 
correlation between the imputed and measured expression for each of the hold out folds during cross 
validation; this measure will be referred to as predicted correlation. The square value of this measure is 
labeled “pred.perf.R2” and will be referred to as predicted R2. Another quality measure is 
“test_R2_avg”, which is the average coefficient of determination for each of the cross-validated models 
and will be referred to as model R2.  
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Considering the stability and “immutability” of DNA i.e., DNA does not change from one tissue to 
another, means one can obtain genetic information from peripheral tissues like whole blood or buccal 
tissue. In contrast, gene expression various among tissues and thus may be more burdensome to obtain, 
especially from internal organs. And with the GTEx transcriptome dataset, the authors of PrediXcan have 
been able to create SQLite weights files for 53 different tissues, with 13 originating within the brain. 
Thus, PrediXcan offers an alternative to circumvent the difficulties associated with generating gene 
expression data from difficult to obtain organs (such as brain) and thus may aid in the study of 
psychiatric ailments.  
 
1.2 PrediXcan in Recent Literature 
As of March 25, 2019, google scholar reported 374 citations for the nature genetics’ publication of 
PrediXcan. Many of these studies referenced the increase power of PrediXcan as the inspiration for their 
study. As users are testing each gene once, with any number of SNPs for a given gene, the multiple 
testing burden is significantly reduced when compared to a single variant eQTL analysis. This count 
potentially reduces the number of tests from the millions to the thousands, depending on the number of 
SNPs in the genotype data and the genes included in the SQLite weights file (Li, 2018). Thus, for many 
studies, PrediXcan is an exploratory tool that was used to confirm measured differential expression and 
find newly differentially expressed genes, which past studies were underpowered to find.  
Many studies take a critical examination of PrediXcan, which is reassuring considering how new this 
software is. One such study examined individuals with amyloid deposition in the brain, which is a risk 
factor for Alzheimer’s Disease, against the GTEx cohort (Hohman, 2018). As this study required a more 
stringent prediction R2 of ≥ 0.15, the authors show restraint in utilizing PrediXcan. More importantly, the 
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authors replicate their findings in another cohort and examined how the results conformed to past 
findings. Lastly, the discussion highlighted many of the limitations with the GTEx transcriptome dataset 
and reiterated the need for the newly identified differentially expressed genes to be validated further.  
 Other studies are far more ambitious in their use of PrediXcan. One study conducted a trans-
ethnic meta-analysis on SNPs associated with breast cancer risk despite that the GTEx transcriptome 
data largely originated from Caucasian donors (Hoffman, 2017). Additionally, they reported significantly 
differentiated genes regardless of the model’s strength; one such gene was DHODH, whose gene model 
had a predicted R2 value of 0.026. But the most concerning element of these studies is that their results 
may be referenced in other papers without sufficient attention to the imputation methodology. One 
such study found that lower expression of RPRD1B was associated with cisplatin-induced peripheral 
neuropathy using PrediXcan (Dolan, 2017). A systematic review of cisplatin toxicity reported the study’s 
findings on RPRD1B with no mention of PrediXcan, imputation, or the elastic net methodology 
(Chovanec, 2017). Thus, there is the possibility that that the results will be given similar weight and 
attention to non-imputation results. If PrediXcan accurately imputes gene expression, such 
interpretations aren’t problematic. But if PrediXcan’s accuracy is low or limited, such interpretations 
could incorrectly define the narrative and hinder scientific inquiry.  
 
1.3 Concerns about PrediXcan Methodology 
Considering PrediXcan ability to overcome limitations with differential expression analysis, it’s use 
has grown overtime. But with any new methodology, it’s important that alongside its benefits, its 
limitations are also considered. Here, 4 such concerns have been identified.  
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I. For the GTEx transcriptome dataset, PrediXcan only includes cis-SNPs (within 1Mb of gene 
start or end) within the model. While testing for cis-SNPs is typical with eQTL analysis, as a 
consequent of the multiple-testing burden (Nica, 2013), large twin studies have asserted 
that trans-SNPs may play a larger role. One study found that only 10% of the genetic 
variance for skin tissue was explained by cis-SNPs (Grundberg, 2012). Additionally, during 
the model-building procedure, ambiguous SNPs (e.g. A/T) were removed so that the 
software could identify and correct genotype dosages given by the user. Thus, a 
considerable amount of genotype information had been eliminated prior to deriving each 
model, which could affect PrediXcan’s performance. 
II. For GTEx v7, the authors required each gene model to have a predicted correlation above 
0.10. Additionally, the p-value for that correlation must be below 0.05. Hence, these quality-
control measures reduced the number of genes within each tissue-specific SQLite weights 
file. For GTEx v7 whole blood, the tissue-specific weight file with the highest average 
predicted R2, only 6,297 genes were included.  
III. Only the top 9 GTEx tissues, which had the largest sample sizes, were evaluated in the 
original manuscript. Both the predicted R2 and model R2 were low for these models. For 
instance, the average predicted R2 for all gene models for whole blood was 0.118 (median 
0.074). Additionally, the average model R2 for all the gene models for whole blood was 
0.096 (median 0.050).  
IV. While the GTEx cohort is fairly inclusive with only a handful of exclusionary criteria, like 
metastatic cancer (GTEx, 2013), the cohort is largely European, skews towards older adults, 
and does not include expression measurements for all donors. For PrediXcan’s tissue-
specific weight files, derived from GTEx v7, only European donors were selected and the 
average number of donors per weight file was around 185. Thus, there is a question about 
8 
 
how well PrediXcan’s methodology can capture the expression differences found in less 
common ailments and populations, which may have not been sufficiently represented in the 
GTEx cohort or tissue-specific samples. Additionally, the general heterogeneity of the cohort 
may lead to higher expression variance and thus limit the power of any models derived from 
it.  
 
1.4 An Opportunity to Evaluate PrediXcan: 
A transcriptome dataset has been made available from deceased donors diagnosed with alcohol 
dependence (n=32) and neurotypical controls (n=31). The tissue was obtained by the Australian Brain 
Donor Program and include Caucasian male (n=54) and females (n=9) that met the inclusion criteria, 
which excluded individuals with infectious disease, significant head trauma, long agonal, and long delays 
in procuring the tissue (McMichael, 2019, pre-print: https://doi.org/10.1101/583203, under review). The 
expression data was obtained from the nucleus accumbens of these donors, which animal models have 
strongly implicated in pavlovian reward-related learning (Day, 2011) and addictive drug behaviors 
(Scofield, 2016). Additionally, eQTL analysis of the nucleus accumbens have shown differential 
expression for those with alcoholism (Mamdani, 2015), including for this particular dataset (McMichael, 
2019). Thus, not only is the organ appropriate for finding differential expression of alcoholics, such 
findings have been demonstrated for hundreds of genes.  
As the PrediXcan authors have made the SQLite weights file available for the nucleus accumbens, 
which was derived from the GTEx version 7 transcriptome dataset, there is an opportunity to assess 
PrediXcan’s methodology. Twin studies have estimated the heritability of alcohol use disorder to range 
from 48-58% (Prescott, 1999). Given this is a disease with a large genetic component, which PrediXcan’s 
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methodology models, the use of PrediXcan for this phenotype is appropriate. Furthermore, studies 
evaluating PrediXcan for assessing psychiatric phenotypes are rare and, to the best of my knowledge, 
have not focused on alcoholism.  
As the nucleus accumbens was not evaluated in the original PrediXcan manuscript and considering 
the general concerns/performance surrounding GTEx weights files, we hypothesize that PrediXcan will 
impute the expression for most genes, which are associated with alcohol use disorder, poorly. That 
being said, the PrediXcan authors calculated the heritability of their Depression Gene Networks model, 
which is based on whole blood samples, and found that the predicted R2 increased with higher 
heritability (Gamazon, 2015). This observation isn’t unusual as the effect sized of cis-eQTLs increase with 
a gene’s heritability (Grundberg, 2012). Additionally, it has been shown that the heritability of gene 
expression is primarily explained by cis loci ---not trans--- in tissues with a heterogenous mixture of cell 
types, as is common with the GTEx datasets (Price, 2011). Thus, it seems reasonable that PrediXcan, 
which utilized models built on cis associations, may be able to accurately impute expression values for 
highly heritable gene. And while heritability estimates for GTEx are unavailable, the fact that heritability 
and predicted R2 are correlated means that predicted R2 can be used as a surrogate. Hence, it is also 
hypothesized that the accuracy of PrediXcan imputation will increase by selecting genes with a high 
predicted R2 model.  
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Chapter 2 
Measuring Differential Expression 
 To gauge PrediXcan’s accuracy, one must first measure the differential expression between 
donors diagnoses with alcohol use disorder and neurotypical controls. The expression measurements of 
the 63 donors were obtained using Arraystar Human LncRNA Array v3.0 (Rockville, MD, USA). This 
platform detects 61,464 transcripts encompassing both protein coding genes and long noncoding RNAs. 
As Arraystar limits information concerning their proprietary probe designs, annotation information was 
available for only 11,810 of those genes (19%) that were found to be differentially expressed (t-value ≥ 
|0.5|) as determined by the methodology of the original manuscript for this transcriptome dataset 
(McMichael, 2019). Additionally, those differential expression results were made available, were labeled 
manuscript results within this work, and were used as a comparison to this work’s methodology.  
 Differential expression analysis was conducted with R version 3.5.1 with the tidyverse package, 
which was used for data wrangling and visualization, and the Linear Models of Microarray Data (Limma) 
package, which handled the statistical elements (Smyth, 2004). Essentially, limma follows the traditional 
approach of determining group differences by building a linear regression model for each probe. But 
instead of using a simple t-test, Limma employs empirical Bayes methodology to “borrow strength” from 
the other probes (Ritchie, 2015). In other words, limma utilizes all probes within the dataset to calculate 
the variance of each individual probe, which ultimately increases the power of the model. But before 
using limma’s toptable function, which produced the results, several considerations were taken into 
account. 
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 First, the raw data was log2-transformed, background corrected using normexp, and had 
controls probes removed from further consideration. Second, each array was examined for irregularities 
utilizing a MA-plot. No irregularities were found, which was likely a result of the transcriptome dataset 
including only arrays used in the final analysis of the original manuscript (i.e. the dataset had 
problematic arrays filtered out). Next, normalization was applied, which reduces the variances found 
between arrays so that they can be compared (Quackenbush, 2002). It should be noted that there is 
considerable debate concerning the best normalization procedure. Quantile normalization, which is 
limma’s default procedure for single-channel arrays, forces each array to have the same distribution. As 
there is no biological reason to expect that the bulk expressed transcriptome will show stark expression 
differences between alcoholics and neurotypical controls, quantile normalization seemed appropriate 
and was selected. 
 Demographic information (age of death, sex, brain weight, hemisphere of sample, 
neuropathology, and smoking status), experimental conditions (Batch, pH of sample, postmortem 
interval from procuring sample, and RNA integrity number) were collected for all samples and checked 
for outliers; no outliers were found, which was expected as the transcriptome dataset has been pre-
screened. As these elements may influence differential expression or measurements of differential 
expression, it is prudent to account for them within the model. But while correcting for confounding 
variables can lead to increased power and more accurate results, over adjusting a model can lead to 
lower power (Kahan, 2014). Thus, a principal component analysis (PCA) was conducted, which captures 
the variance of potential demographic/experimental confounders as principal components (PCs).  
R’s prcomp function was used to conduct the PCA. A scree plot was used to identify the 
inflection point of the PCs’ eigenvalues. The 3 PCs to the left of the inflection point were retained as 
those PCs explained a substantial amount of variance in the demographic/experimental data. R’s 
varimax function was used on the loadings of each PC in order to aid in interpreting and verification of 
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the PCA results. The correlation between each of the potential confounding variables and the retained 
PCs with varimax rotation are displayed in Table 1.   
 
Variable PC1 PC2 PC3 
Batch -0.661 0.240 0.382 
Age of Death -0.362 -0.153 0.203 
Sex -0.828 0.164 -0.097 
Brain Weight 0.620 0.310 0.108 
pH 0.147 -0.165 -0.796 
Postmortem Interval -0.053 -0.587 0.112 
Hemisphere 0.166 -0.191 0.676 
Neuropathology  -0.135 -0.683 0.200 
Smoking Status -0.116 0.591 0.225 
RNA Integrity 0.464 0.214 -0.609 
Table 1: Correlation between potential confounding variables and retained principal components, which 
were produced by the prcomp function and manual varimax rotation.  
 
 The differential expression of each gene was tested using a robust linear regression, which was 
adjusted with the top three unrotated PCs. t-values were selected to make comparisons between 
limma’s results and the manuscript results. The histograms of both approaches can be seen in figure 1. 
The Pearson correlation between the t-values of both approaches was 0.92 and the corresponding 
scatter plot can be viewed in figure 2. Note: whitespace found in the manuscript’s histogram and scatter 
plot were caused by the incomplete annotation.  
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Figure 1. Histogram of t-values calculated by 
Limma, using empirical Bayes methodology, and 
the manuscript’s methodology.  
Figure 2. Scatter plot of comparable t-values 
calculated by Limma, using empirical Bayes 
methodology, and the manuscript’s 
methodology. 
 
 A Venn diagram was provided in Figure 3, which compared t-values ≥ |3.25| from Limma’s 
empirical Bayes methodology and the manuscript’s methodology; this roughly corresponds to a False 
Discovery Rate p-value of 0.05. As there was a strong Pearson correlation between both techniques, 
these initial results suggest that the empirical Bayes test is slightly inflating the t-values. That being said, 
it’s imperative to test this inclination.  
 
Figure 3. Venn diagram of t-values ≥ |3.25| with Limma, using the empirical Bayes methodology, and 
the manuscript’s methodology.  
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2.1 Limma without Empirical Bayes 
 In order to perform differential expression, Limma interacts with an expression object, which is 
modified at each step. The toptable function, which outputs the results, is dependent on the empirical 
Bayes function to calculate and apply certain test-statistics (t-values, p-values, and log-odds) onto the 
expression object. Thus, Limma does not offer a way to disable the empirical Bayes methodology. But by 
manually calculating and applying those test-statistics to the expression object, one can circumvent the 
Bayes methodology with another. Thus, the same methodology was followed except a simple t-test was 
performed and the necessary test-statistics were manually added to the expression object prior to using 
the toptable function.  
  A histogram (Figure 4), scatter plot (figure 5) and Venn diagram (figure 6) of Limma without the 
empirical Bayes methodology are provided below. The Pearson correlation between comparable t-
values was 0.92. Thus, the differences between the two methods were minor, suggesting that the 
empirical Bayes methodology was not responsible for the inflation of t-values. In fact, there was a slight 
increase of t-values ≥ |3.25| with the simple t-test, suggesting that the empirical Bayes methodology 
was deflating ---not inflating--- the t-values. This could be caused by a number of probes having an 
unusually low variances, which Limma was correcting. 
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Figure 4. Histogram of t-values calculated by 
Limma, using a simple t-test, and the 
manuscript’s methodology.  
Figure 5. Scatter plot of comparable T-values 
calculated by Limma, using a simple t-test, and 
the manuscript’s methodology. 
 
 
 
Figure 6. Venn diagram of t-values ≥ |3.25| with Limma, using a simple t-test, and the manuscript’s 
methodology.  
 
2.2 Limma using NCSS Derived Principal  Component Analysis. 
 The manuscript methodology differed from this work in several ways which included its handling 
of normalization, accounting for batch effect, and removal of probes. That being said, batch effect tends 
to be one of the most prominent confounding elements in microarray platforms and the prcomp 
function (Table 1) did not appear to account for much of the batch variance. Thus, there were concerns 
that the original PCA did not properly account for confounding variables. Following the manuscript as a 
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rough guideline, NCSS version 12 was used to perform a robust PCA with a varimax rotation. The top 3 
PCs were still retained. As the NCSS software utilizes a version of the modern QL algorithm, it’s was 
expected to produce different loadings from the prcomp function. The correlation between the 
variables and the 3 rotated PCs are displayed in Table 2. Additionally, a histogram (Figure 7), scatter plot 
(figure 8) and Venn diagram (figure 9) of Limma with the empirical Bayes methodology with NCSS PCA 
were also provided. 
 
Variable PC1 PC2 PC3 
Batch 0.755 -0.051 -0.300 
Age of Death 0.490 0.181 0.048 
Sex 0.791 -0.037 0.024 
Brain Weight -0.348 -0.390 0.044 
pH -0.204 0.002 0.836 
Postmortem Interval 0.001 0.636 0.096 
Hemisphere -0.189 0.264 -0.642 
Neuropathology  -0.051 0.727 -0.141 
Smoking Status 0.168 -0.458 -0.437 
RNA Integrity -0.501 -0.426 0.435 
Table 2: Correlation between potential confounding variables and retained principal components, which 
were produced by NCSS’s robust PCA with varimax rotation.  
 
  
Figure 7. Histogram of t-values calculated by 
Limma (left) and manuscript’s methodology 
(right).  
Figure 8. Scatter plot of comparable t-values 
calculated by Limma and the manuscript’s 
methodology.  
 
Note: Limma utilized empirical Bayes methodology. The model was adjusted utilizing PCs derived 
from NCSS. 
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Figure 9. Venn diagram of t-values ≥ |3.25| with Limma and the manuscript’s methodology. Limma 
utilized empirical Bayes methodology. The model was adjusted utilizing PCs derived from NCSS. 
 The Pearson correlation slightly improved to 0.94 and the number of probes, with a t-value ≥ 
|3.25|, decreased. That being said, the differences between prcomp and NCSS were not substantial, 
highlighting that the original analysis (Limma, empirical Bayes, prcomp) had an adequate PCA. 
Additionally, the original analysis produced a Pearson correlation of 0.92 and a non-significant Wilcoxon 
rank sum test (p-value = 0.97). Thus, while there may be substantial nonoverlapping in the Venn 
diagram, that result was caused by slight variations ---not stark differences--- in the t-values. Considering 
those factors, the original analysis seemed appropriate and was used as a base comparison for 
PrediXcan.  
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Chapter 3  
Evaluating Imputed Expression 
 The genotype data of the transcriptome dataset, which included donors with alcohol use 
disorder, originated from the Affymetrix Genome-Wide Human SNP Array 6.0 platform. The data had 
been pre-imputed and filtered to exclude SNPs with a low (≤ 0.01) minor allele frequency (MAF). In total, 
3,703,165 autosomal SNPS were provided with annotations. The GTEx version 7 nucleus accumbens 
SQLite weight file was downloaded from predictdb.org, which was built using the genotypic and 
expression data from 114 donors. This file contains weights for 113,923 SNPs that were associated with 
3,633 genes; 2,641 were protein-coding (73%), 485 were long non-coding RNAs (13%), and 507 were 
pseudogenes (14%).  
 Python 3.7 was used to transform the genotype data into a PrediXcan dosage files, which are 
chromosome-specific compressed files containing the genotype information and SNP annotations. 
Because PrediXcan cannot handle NA values, which relate to unknown calls, SNPs with any NAs were 
removed from further consideration. This reduced the initial number of SNPs to 2,217,199 (60% of the 
original dataset). Finally, a sample file, which helps PrediXcan identify samples, and a phenotype file, 
which is used during PrediXcan’s association test, were created.  
Several quality checks were conducted before running PrediXcan. First, GTEx used the human 
genome reference GRCh37; thus, the genotype annotation was compared to ensure both the SNP 
position and allele information matched Ensembl’s GRCh37 build. R version 3.5.1 with the biomaRt 
package (Durinck, 2011) was used to retrieve and compare annotations. No discrepancies were found. 
Secondly, the SQL weight files do not follow the alternative/reference convention due to annotation 
discrepancies between different databases. Instead, the weight file reference the “effect allele” and only 
include non-complementary SNPs, which allows PrediXcan to correct dosages if the other allele was 
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coded for. Still, the transformed genotype files were checked against the SQLite weight file for coding 
discrepancies; none were found.  
Python 2.7 on Ubuntu 18.04.1 LTS was used to run PrediXcan, which produced imputed 
expression levels for each individual. Several steps were taken so that the imputed expression could be 
compared against the measured expression. First, the PrediXcan output included Ensembl gene IDs, 
which were not available in the Arraystar annotation. Thus, Python 3.7 with the MyGene package (Xin, 
2016) was used to convert the IDs into gene symbols. Secondly, a handful of genes, which were found in 
the measured expression, had duplicate probes (n=11). The median values of those probes were taken. 
Finally, PrediXcan works in an additive fashion where all genes start with an initial value of zero. If the 
output of a gene includes zeros for all imputed individuals, that indicates that the genotypic data lacked 
matching SNPs in the weights file. Thus, these genes were removed (n=411) as they weren’t informative.  
As the gene models were trained on log2 inverse-rank normalized data, the measured 
expression data was transformed in the same manner. Thus, the imputed expression results could be 
negative and would indicate that the predicted expression was lower than the average expression of the 
GTEx cohort, which was used to create the model. For genes in both datasets, a Pearson correlation was 
used to compare measured expression values and imputed expression values (Table 3). Additionally, the 
genes with the highest Pearson correlation are highlighted in Figure 10.  
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 ALL PR2≥0.1 PR2≥0.2 PR2≥0.3 PR2≥0.4 PR2≥0.5 PR2≥0.6 
Number of Genes: 975 546 262 142 69 25 10 
First 5 with AUD:        
1 -0.042 -0.065 -0.039 0.031 -0.116 -0.148 0.195 
2 -0.007 -0.030 -0.098 -0.069 -0.087 0.095 0.131 
3 0.004 0.049 0.019 -0.027 0.011 0.037 -0.234 
4 -0.017 -0.051 -0.104 -0.114 -0.097 -0.091 -0.280 
5 0.014 0.017 0.114 0.137 0.177 0.387 0.751 
        
First 5 Controls:        
1 0.011 0.017 0.001 -0.031 0.006 0.022 0.076 
2 -0.002 -0.026 -0.078 -0.104 -0.051 0.169 0.826 
3 0.013 0.044 0.100 0.081 -0.016 0.128 -0.019 
4 -0.027 -0.035 -0.038 -0.133 -0.032 -0.272 -0.504 
5 -0.005 0.022 0.016 -0.010 -0.117 -0.114 -0.251 
        
Mean (All Donors) 0.021 0.012 0.016 0.022 0.003 0.054 0.043 
SD (All Donors) 0.193 0.219 0.256 0.286 0.323 0.320 0.317 
Table 3. Pearson correlation of matching genes between measured expression and imputed expression 
for a given individual. The first 5 donors with alcohol use disorder and neurotypical controls were 
highlighted. Pearson correlation of matching genes were also calculated at certain predicted R2 
thresholds (≥0.1, ≥0.2,  ≥0.3, ≥0.4, ≥0.5, or ≥0.6). 
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Figure 10: Examples of well predicted genes. The predicted R2 for SPSB2, ELAC2, SMYD4, and LRRC37A 
was 0.418, 0.323, 0.139, 0.531. 
 
 The results show that only 975 genes were matched between the imputed expression and 
measured expression. Overall, the correlation was poor and did not significantly improve by selecting 
genes with a specified predicted R2. There were a handful of well correlated genes (Figure 10) but only 
13 genes had a Pearson correlation ≥ 0.5 (1.3% of all matched genes). And while most of those genes 
had a predicted R2 above the average gene model, which was 0.16 for the nucleus accumbens, none of 
those genes had a strong predicted R2. 
 Additionally, some of the well correlated genes had defined striations, which suggests that 
much of the imputed expression was defined by a single SNP. For example, the most likely explanation 
for ELAC2’s results would be a single SNP, with a high weight coefficient, and a somewhat even-
22 
 
distribution of the three genotypes (homozygous major, heterozygous, and homozygous minor). The 
jittering of those lines was likely the result of other SNPs with a lower weight coefficient. This 
observation is further supported by the fact that ELAC2 has only 7 SNPs in its gene model (on average, 
nucleus accumbens’ gene models contained 31 SNPs).  
 
3.1 Selecting Genes with Model R2  
 In the SQLite weight files for GTEx version 7, the model R2 quality metric was added. This metric 
is the average coefficient of determination for each of the cross-validated models. As such, it expresses 
how much variance a particular model is able to account for. Thus, the metric may be a stronger 
indicator of a model’s accuracy and was used to select genes (Table 4). Overall, the correlations did not 
improve by selecting genes with a higher model R2. The differences between the model R2 and the 
predicted R2 were not substantial.  
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 ALL MR2≥0.1 MR2≥0.2 MR2≥0.3 MR2≥0.4 MR2≥0.5 MR2≥0.6 
Number of Genes: 975 343 188 98 46 19 6 
First 5 with AUD:        
1 -0.042 -0.060 0.045 -0.077 -0.093 -0.160 0.168 
2 -0.007 -0.071 -0.062 -0.129 0.082 0.188 0.041 
3 0.004 0.030 -0.023 -0.023 -0.113 0.032 -0.328 
4 -0.017 -0.089 -0.090 -0.092 -0.102 -0.148 -0.229 
5 0.014 0.045 0.167 0.173 0.123 0.409 0.935 
        
First 5 Controls:        
1 0.011 0.000 0.009 -0.080 -0.022 0.024 0.284 
2 -0.002 -0.026 -0.092 -0.107 -0.012 0.240 0.933 
3 0.013 0.078 0.101 0.065 -0.025 0.285 -0.021 
4 -0.027 -0.033 -0.106 -0.122 -0.179 -0.325 -0.450 
5 -0.005 0.002 0.024 -0.020 -0.074 -0.162 -0.324 
        
Mean (All Donors): 0.021 0.022 0.031 0.002 -0.021 0.026 -0.012 
SD (All Donors): 0.193 0.237 0.271 0.298 0.323 0.294 0.383 
Table 4. Pearson correlation of matching genes between measured expression and imputed expression 
for a given individual. The first 5 donors with alcohol use disorder and neurotypical controls were 
highlighted. Pearson correlation of matching genes were also calculated at certain model R2 thresholds 
(≥0.1, ≥0.2,  ≥0.3, ≥0.4, ≥0.5, or ≥0.6). 
 
3.2 Recoding Missing SNPs 
 As PrediXcan cannot handle missing values, SNPs with any NAs were removed from further 
consideration. Thus, a single NA would cause all genotypic data for that SNP to be disregarded, which is 
reflected in the fact that 40% of the genotypic data was removed. As PrediXcan depends on matching 
SNPs to the SQLite weight file, there was a strong possibility that the filtering step eliminated predictive 
information and hampered PrediXcan’s accuracy. Thus, recoding missing values was attempted by 
assigning them the value [2 X Population’s Effect Allele]. This step ascribes a neutral estimator to each 
missing SNP by assuming the sample’s genotype matched the allele frequency in its population.  
The National Center for Biotechnology Information (NCBI) provides comprehensive information 
about each SNP, including allele frequencies for different populations. Additionally, the URL of a given 
SNP is predictive, allowing one to automate the retrieval of relevant information. Thus, a virtual private 
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server running ubuntu 18.04.2 LTS executed a bash script, which visited and extracted allele frequencies 
for 1,485,966 SNPs. Considering that the donors were Caucasian Australians, the European population 
was chosen. Information relating to 973,016 SNPs had allele frequencies for the European population. 
That information was checked against the annotations for mismatch alleles and nonsensical results (i.e. 
same nucleic acid for the reference and alternative allele); 7,931 results were removed due to quality-
control measures. Thus, 965,085 SNPs were able to be recoded, which increased the total number of 
SNPs available for PrediXcan to 3,182,284 (86% of the original dataset).  
The results of the recoding are highlighted in table 4. As more SNPs were included, there were 
less genes removed for having all imputed zeros (n=333) and slightly more matching genes (n=999). And 
while filtering by predicted R2 brought a slight improvement in the mean correlation, PrediXcan accuracy 
remain poor and only 14 genes had a Pearson correlation ≥ 0.5 (1.4% of all matched genes). Additionally, 
the genes with the highest correlation did not change. Thus, recoding missing values brought minor 
improvements. 
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 ALL PR2≥0.1 PR2≥0.2 PR2≥0.3 PR2≥0.4 PR2≥0.5 PR2≥0.6 
Number of Genes: 999 558 265 144 70 25 10 
First 5 with AUD:        
1 -0.041 -0.052 -0.037 0.000 -0.153 -0.233 0.249 
2 0.031 0.009 -0.042 -0.036 -0.084 0.088 0.181 
3 0.020 0.074 0.068 0.031 0.086 0.101 -0.083 
4 -0.035 -0.045 -0.098 -0.114 -0.132 -0.087 -0.132 
5 0.032 0.039 0.098 0.101 0.153 0.278 0.722 
        
First 5 Controls:        
1 0.020 0.010 -0.008 -0.035 -0.030 0.070 0.117 
2 -0.009 -0.042 -0.121 -0.186 -0.207 -0.086 0.580 
3 0.014 0.027 0.064 0.069 -0.032 0.142 0.058 
4 -0.006 -0.009 -0.016 -0.102 - 0.047 -0.262 -0.595 
5 -0.017 0.017 0.015 0.006 -0.066 -0.055 -0.175 
        
Mean (All Donors): 0.025 0.020 0.024 0.031 0.025 0.060 0.050 
SD (All Donors): 0.194 0.219 0.253 0.283 0.318 0.323 0.309 
Table 5. Pearson correlation of matching genes between measured expression and imputed expression 
for a given individual. Missing dosages in genotype data was recoded prior to using PrediXcan. The first 5 
donors with alcohol use disorder and neurotypical controls were highlighted. Pearson correlation of 
matching genes were also calculated at certain predicted R2 thresholds (≥0.1, ≥0.2,  ≥0.3, ≥0.4, ≥0.5, or 
≥0.6). 
 
3.3 Association Test 
If given a phenotype file, to distinguish what group each sample belonged to, PrediXcan can run 
an association test. Thus, a linear association test was performed using the data that had missing SNPs 
recoded. The Benjamani and Hochberg adjusted p-values were calculated with the p.adjust function in R 
version 3.5.1. None of the genes reached significance (≤0.05).  
For exploratory reasons, genes with significant (≤0.05) unadjusted p-values were examined. In 
total, 164 genes were identified and 49 of those genes were represented in the Arraystar annotation. Of 
those 49 genes, only 2 (NOC3L and IFITM4P) were significant in the differential expression analysis of 
the measured expression. Additionally, those genes’ Pearson correlations, which compared the imputed 
and measured expression, are shown in Figure 11. Both of those genes had a modest Pearson 
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correlation and poor predicted R2. Thus, the association test performed poorly, which is understandable 
given the poor imputation of expression.  
 
  
Figure 11. Pearson correlation of two genes, which were significant in the differential expression 
analysis (p-value adjusted) and PrediXcan association test (p-value unadjusted). The Pearson correlation 
and predicted R2 for NOC3L (0.057) and IFITM4P(0.050) were low.  
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Chapter 4 
Affymetrix Expression 
 As part of another study on the same population, expression data was collected utilizing the 
Affymetrix GeneChip Human Genome U133A 2.0 platform, which measured the expression of 18,400 
human transcripts and variants. Only a subset of the neurotypical controls (n=18) and donors with 
alcohol use disorder (n=18). While there are numerous differences between the two platforms, 
including RNA preparation and scanner, one impactful difference is the size of the probes. Affymetrix 
utilizes 25-mer oligonucleotide probes whereas the Arraystar platform are more than double in length 
(60 nt). As shorter probes tend to be more sensitive and longer probes have a higher rate of cross-
hybridization (Chou, 2004), discrepancies may exist between different platforms. 
 Thus, PrediXcan was evaluated against the Affymetrix array using the same procedure as 
described in chapter 3 with several exceptions. First, the data was not log2 transformed, background 
corrected, or normalized, as it was already done as described in the data’s publication (Mamdani, 2015). 
Secondly, the annotations for the platform were created using Affymetrix’s batch query web app 
(https://www.affymetrix.com/analysis/netaffx/batch_query.affx). Additionally, the genotypic data with 
recoding of missing SNPs was used. The results are highlighted in table 6. 
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 ALL PR2≥0.1 PR2≥0.2 PR2≥0.3 PR2≥0.4 PR2≥0.5 PR2≥0.6 
Number of Genes: 1500 832 390 193 91 36 9 
First 5 with AUD:        
1 0.049 0.057 0.050 0.137 0.189 0.301 0.442 
2 0.084 0.104 0.128 0.108 0.171 0.049 0.036 
3 0.022 0.031 0.107 0.121 0.105 0.261 0.403 
4 0.026 0.029 0.060 0.078 -0.019 0.164 0.050 
5 -0.005 -0.039 0.006 0.029 -0.007 0.092 0.098 
        
First 5 Controls:        
1 0.006 0.012 0.027 0.054 0.014 -0.198 -0.010 
2 -0.004 0.020 0.008 0.014 -0.026 0.074 0.328 
3 0.045 0.061 0.090 0.088 0.076 -0.077 -0.229 
4 0.054 0.095 0.072 0.053 0.075 0.213 0.576 
5 -0.027 0.007 0.003 0.011 0.006 0.119 0.192 
        
Mean (All Donors): 0.025 0.033 0.046 0.058 0.054 0.026 0.099 
SD (All Donors): 0.239 0.264 0.301 0.336 0.374 0.423 0.415 
Table 6. Pearson correlation of matching genes between the Affymetrix measured expression and 
imputed expression for a given individual. Missing dosages in genotype data was estimated prior to 
using PrediXcan. The first 5 donors with alcohol use disorder and neurotypical controls were highlighted. 
Pearson correlation of matching genes were also calculated at certain predicted R2 thresholds (≥0.1, 
≥0.2,  ≥0.3, ≥0.4, ≥0.5, or ≥0.6). 
  
 The fact that only 1,500 genes matched between the Affymetrix platform and the PrediXcan 
results were surprising for several reasons. First, the nucleus accumbens weight file included 2,641 
protein coding genes. Additionally, the Affymetrix platform attempts to capture the entire protein 
coding transcriptome, which may only total 19,000 genes for humans (Ezkurdia, 2014), and more 
importantly, makes the full annotations available. Thus, the protein coding genes within the weight file 
were examined further; numerous protein coding genes included read-throughs, putative and variant 
genes were discovered, which explained the lower than expected matching.  
The correlation between Imputed expression and Affymetrix expression are show in Figure 12 
and show the top correlated genes all had a predicted R2 above the average (i.e. 0.16). But overall, the 
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accuracy of PrediXcan was poor and increasing the predicted R2 did not bring a substantial gain in 
performance. Only 41 genes (2.7% of all matched genes) had a Pearson correlation ≥ 0.5. 
 
 
  
  
Figure 12: Examples of well predicted genes. GPNMB, LINC00339, SLC35F2, and GSTM5 had a predicted 
R2 of 0.308, 0.521, 0.390, and 0.494.  
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Chapter 5 
Lung cohort 
 While PrediXcan’s performance was evaluated on two different platforms, the poor correlation 
may have been the consequence of any number of coding errors (i.e. incorrect annotations, incorrect 
dosage file format, etc) rather than a true measure of PrediXcan’s accuracy. Unfortunately, the GTEx 
transcriptome dataset is not readily available, which prevented us from reproducing the findings of the 
original PrediXcan paper. Thus, to evaluate the previous chapters’ methodology, the NCBI’s Gene 
Expression Omnibus (GEO) was used to find a transcriptome dataset that offered the greatest likelihood 
of validating PrediXcan’s imputation. This meant selecting a dataset that would be used alongside one of 
PrediXcan’s more robust models (i.e. included a higher number of samples in the model), one that 
matched the donors used in PrediXcan’s models (i.e. Europeans), and one that included healthy tissue.  
The genotypic and small airway epithelium expression data from 15 healthy non-smoking 
European donors were selected from a larger publicly available transcriptome dataset (Butler, 2011). 
This dataset was downloaded from NCBI’s GEO site on February 7th, 2019 (GEO ID: GSE22047). 
Additionally, this dataset contained similar platforms for the genotypic data (Affymetrix Genome-Wide 
Human SNP 5.0 Array) and expression data (Affymetrix Human Genome U133 Plus 2.0 Array). In total, 
preprocessed genotypic data pertaining to 443,816 SNPs and expression data pertaining to around 
47,000 transcripts was provided. The lung SQLite weights file was selected, which utilized the GTEx v7 
transcriptome dataset and incorporated information from 333 donors. The file included weights for 
209,035 SNPs, which were associated with 7,968 genes; 6,145 were protein-coding (77%), 940 were long 
non-coding RNAs (12%), and 883 were pseudogenes (11%). Compared to the nucleus accumbens’ 
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weights file, there were substantially more GTEx donors incorporated in the gene models (192%) and 
more genes (119%). 
The methodology for this chapter closely follows chapter 3 with a few exceptions. First, the data 
was not background corrected or normalized as those steps were conducted as specified in the dataset’s 
manuscript (Butler, 2011). Secondly, the expression annotation provided on the dataset’s GEO page was 
used. As this annotation included the Ensembl stable IDs, those IDs were used instead of gene symbols 
for comparisons between the imputed and measured expression.  
Prior to comparing the results, the imputed expression of 1,374 genes were removed due to all 
individuals having a value of zero (i.e. non-informative imputation). In total, 3,735 genes matched, which 
is likely the consequence of many more genes modeled in the SQLite weights file. The results are 
highlighted in table 7 and show a consistent improvement in the correlation by using predicted R2 for 
filtering. The top 4 genes, with the highest Pearson correlation, are shown in figure 13; the gene models 
for these genes all had a substantially higher predicted R2 than the average predicted R2 in the lung 
SQLite weights file, which was 0.11. Only 41 genes (1.09% of matched genes) had a Pearson correlation 
≥ 0.5. 
Overall, the results highlight PrediXcan’s ability to predict some genes well and validate the 
notion of using predicted R2 as a metric to increase imputation quality. It should be noted that the GTEx 
expression data comes from tissue found 1 cm below the pleural surface of the lung, which is a 
heterogenous mixture of different cell types. As the expression data originated from a particular cell 
type (small airway epithelium), the results also give support to PrediXcan’s methodology, which has 
been used to model genes within heterogenous tissue. 
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 ALL PR2≥0.1 PR2≥0.2 PR2≥0.3 PR2≥0.4 PR2≥0.5 PR2≥0.6 
Number of Genes: 3735 1450 626 320 158 69 16 
First 5 Individuals:        
1 0.049 0.084 0.102 0.149 0.218 0.169 0.200 
2 0.035 0.091 0.126 0.217 0.220 0.309 0.502 
3 0.007 0.033 0.082 0.131 0.079 0.146 0.300 
4 0.023 0.018 0.095 0.101 0.208 0.176 0.348 
5 0.054 0.063 0.119 0.173 0.163 0.103 0.344 
        
Mean (All Donors): 0.049 0.088 0.124 0.181 0.213 0.268 0.365 
SD (All Donors): 0.275 0.301 0.318 0.313 0.314 0.320 0.378 
Table 7. Pearson correlation of matching genes between the measured expression and imputed 
expression of lung tissue for a given individual. The first 5 donors were highlighted. Pearson correlation 
of matching genes were also calculated at certain predicted R2 thresholds (≥0.1, ≥0.2,  ≥0.3, ≥0.4, ≥0.5, 
or ≥0.6). 
 
  
  
Figure 13: Examples of well predicted genes. CECR1, FAM118A, MARCH2, and SLC7A9 had a predicted R2 
of 0.306, 0.703, 0.365, and 0.267. 
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Chapter 6 
Discussion 
 From the onset of this study, there had been two main goals. Firstly, evaluating PrediXcan ability 
to identify differential expression between donors with alcohol use disorder and neurotypical controls 
and secondly, assessing whether the predicted R2 metric can be used to improve imputation quality. On 
both accounts the performance of PrediXcan was poor regardless of phenotype and tissue origins. 
However, the results did not invalidate PrediXcan’s methodology altogether. PrediXcan was able to 
predict a handful of genes well and those genes largely had a predicted R2 metric above the average 
gene model, which indicates that the well-predicted genes are not a factor of chance alone. Additionally, 
the lung dataset demonstrated that the predicted R2 metric could be used to filter out poorly 
performing gene models and improve imputation. Considering that predicted R2 is a surrogate for 
heritability, the results show that the strong performance of select genes is a consequence of high 
heritability.  
 Despite some of the propitious results of this study, there are apparent limitations to PrediXcan 
that urge a cautionary approach. Most apparent is the fact that the majority of the genes are not 
represented within each of the PrediXcan’s tissue specific weights file. Additionally, the overall 
imputation quality with the alcohol use disorder dataset and lung dataset was poor. And if one utilizes a 
quality metric to limit genes with a high predicted R2 or model R2, the number of genes quickly is 
reduced. For instance, only 36 genes in the lung dataset could be compared when selecting gene models 
with a predicted R2 ≥ 0.5. On this basis alone, PrediXcan cannot replace traditional differential 
expression studies.  
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But even if one accepted those limitations, the well predicted genes highlight another concern. 
Despite these genes having predicted R2 metrics above the average gene model in their weights file, 
these genes often did not have a strong predicted R2. Put in another way, genes with higher quality 
metrics were not imputed with greater accuracy. This shortcoming can also be seen in the lung dataset, 
where the improved correlations markedly fell short of the predicted R2 quality metric. As that metric is 
itself a correlation2, one would expect the opposite. Additionally, it is worth mentioning that only a small 
percentage of compared genes (1.1%-2.7%) had a Pearson correlation ≥ 0.5 between the measured and 
imputed expression. Thus for the lung tissue, where the average correlation improved by filtering out 
genes with a low predicted R2, that average was largely being driven by weak to modest correlations. 
Together, these factors not only highlight the rarity of strong models but an inability to discern strong 
models from weak models, which may lead to spurious results and mislead researchers.  
While the notion of imputing gene expression from genotypic data alone may seem unreliable, 
especially considering the dynamic nature of gene expression, we did observe some limited success in 
the results. Thus while PrediXcan will likely not replace traditional approaches to measure gene 
expression, the authors nonetheless have laid a foundation for future development. For example, 
EpiXcan is another recent software, which builds upon that concept by incorporating epigenomic data 
into its models and reportedly outperforms PrediXcan (Zhang, 2019, pre-print: 
https://dx.doi.org/10.1101/532929). However, we have not tested EpiXcan here.  
Given the merit in PrediXcan’s methodology, it is our intention to continue to understand and 
explore ways to improve PrediXcan’s imputation. Recently, we’ve been given access to genotypic and 
expression data from 326 Australian twins (Powell, 2012). As this cohort is from the same population as 
those in the alcohol use disorder dataset, it will allow us to also calculate narrow sense heritability of 
gene expression and thus circumvent the need for a surrogate quality metric. Additionally, we’ve 
applied for and have obtained access to the GTEx v7 transcriptome dataset. With this data, we will be 
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able to rebuild PrediXcan models, enact different quality control metrics, and attempt to improve the 
results of PrediXcan. Also, our access to the GTEx dataset may allow us to understand why the nucleus 
accumbens tissue performed so poorly. While the lower number of donors included in the elastic net 
methodology are a prime suspect, this can be tested by creating a lung model with the same number of 
donors and observing the outcome.  
  
36 
 
Bibliography  
  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn 
(American Psychiatric Association, 2013). 
Butler, M. et al. Modulation of Cystatin A Expression in Human Airway Epithelium Related to 
Genotype, Smoking, COPD and Lung Cancer. Cancer Res 71, 2572–2581 (2011). 
Byerly, S. et al. Effects of ozone exposure during microarray posthybridization washes and 
scanning. J. Mol. Diagnostics 11, 590–597 (2009). 
Chou, C. C., Chen, C. H., Lee, T. T. & Peck, K. Optimization of probe length and the number of 
probes per gene for optimal microarray analysis of gene expression. Nucleic Acids Res. 32, (2004). 
Chovanec, M. et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann. Oncol. 28, 
2670–2679 (2017). 
Day, J. & Carelli, R. The Nucleus Accumbens and Pavlovian Reward Learning. Neuroscientist. 13, 
148–159 (2007). 
Dolan, M. E. et al. Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral 
Neuropathy in Survivors of Adult-Onset Cancer. Clin Cancer Res. 23, 5757–5768 (2017). 
Durinck, S., Spellman, P., Birney, E. & Huber, W. Mapping Identifiers for the Integration of 
Genomic Datasets with the R/Bioconductor package biomaRt. Nat Protoc 4, 1184–1191 (2011). 
 Ezkurdia, I. et al. Multiple evidence strands suggest that there may be as few as 19 000 human 
protein-coding genes. Hum. Mol. Genet. 23, 5866–5878 (2014). 
 Feeney, G. F. X., Connor, J. P., Young, R. M. D., Tucker, J. & McPherson, A. Combined 
acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone 
for alcohol abstinence: A single centres’ experience with pharmacotherapy. Alcohol Alcohol. 41, 321–
327 (2006). 
Ferrer, I., Martinez, A., Boluda, S., Parchi, P. & Barrachina, M. Brain banks: Benefits, limitations 
and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank. 9, 
181–194 (2008). 
 Gamazon, E. R. et al. A gene-based association method for mapping traits using reference 
transcriptome data. Nat. Genet. 47, 1091–1098 (2015). 
 Garneau, N. L., Wilusz, J. & Wilusz, C. J. The highways and byways of mRNA decay. Nat. Rev. 
Mol. Cell Biol. 8, 113–126 (2007). 
 Gowon O. McMichael, John Drake, Eric Sean Vornholt, Kellen Cresswell, Vernell Williamson, 
Chris Chatzinakos, Mohammed Mamdani, Siddharth Hariharan, Kenneth S. Kendler, Michael F. Miles, 
Gursharan Kalsi, Brien P. Riley, Mikhail Dozmorov, Silviu-Alin Bacanu, V. I. V. Assessing the role of long-
noncoding RNA in nucleus accumbens in subjects with alcohol dependence. pre-print bioRxiv (2019). 
doi:https://doi.org/10.1101/583203 
37 
 
 Grant, B. F. et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National 
Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 72, 757–766 (2015). 
 Grundberg, E. et al. Mapping cis - and trans -regulatory effects across multiple tissues in twins. 
Nat Genet. 44, 1084–1089 (2012). 
 Hasin, D., Stinson, F., Ogburn, E. & Grant, B. Prevalence, Correlates, Disability, and Comorbidity 
of DSM-IV Alcohol Abuse and Dependence in the United States. Arch. Gen. Psychiatry 64, 830–842 
(2008). 
Hoffman, J. D. et al. Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated 
with breast cancer risk. PLoS Genet. 13, 1–19 (2017). 
 Hohman, T. J., Dumitrescu, L., Cox, N. J. & Jefferson, A. L. Genetic resilience to amyloid related 
cognitive decline. Brain Imaging Behav. 11, 401–409 (2017). 
 Kahan, B. C., Jairath, V., Doré, C. J. & Morris, T. P. The risks and rewards of covariate adjustment 
in randomized trials: An assessment of 12 outcomes from 8 studies. Trials 15, 1–7 (2014). 
 Laramée, P. et al. Risk of All-Cause Mortality in Alcohol-Dependent Individuals: A Systematic 
Literature Review and Meta-Analysis. EBioMedicine 2, 1394–1404 (2015). 
 Leek, J. T. Tackling the widespread and critical impact of batch effects in high-throughput data. 
Nat Rev Genet 11, 1–15 (2010). 
 Li, B. et al. Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene 
expression. Pac Symp Biocomput 23, 448–459 (2018). 
 Malo, N., Libiger, O. & Schork, N. J. Accommodating Linkage Disequilibrium in Genetic-
Association Analyses via Ridge Regression. Am. J. Hum. Genet. 82, 375–385 (2008). 
 Mamdani, M. et al. Integrating mRNA and miRNA weighted gene co-expression networks with 
eQTLs in the nucleus accumbens of subjects with alcohol dependence. PLoS One 10, 1–28 (2015). 
 Nica, A. C. & Dermitzakis, E. T. Expression quantitative trait loci: present and future. Philos. 
Trans. R. Soc. B-Biological Sci. 368, (2013). 
 Powell, J. E. et al. Genetic control of gene expression in whole blood and lymphoblastoid cell. 
Genome Res. 22, 456–466 (2012). 
 Prescott, C. A. & Kendler, K. S. Genetic and environmental contributions to alcohol abuse and 
dependence in a population-based sample of male twins. Am. J. Psychiatry 156, 34–40 (1999). 
 Price, A. L. et al. Single-tissue and cross-tissue heritability of gene expression via identity-by-
descent in related or unrelated individuals. PLoS Genet. 7, (2011). 
 Quackenbush, J. Microarray data normalization and transformation. Nat. Genet. 32, 496–501 
(2002). 
Ray, L. A., Bujarski, S., Roche, D. J. O. & Magill, M. Overcoming the ‘Valley of Death’ in 
Medications Development for Alcohol Use Disorder. Alcohol. Clin. Exp. Res. 42, 1612–1622 (2018). 
38 
 
 Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and 
microarray studies. Nucleic Acids Res. 43, e47 (2015). 
 Roerecke, M. & Rehm, J. Alcohol use disorders and mortality: A systematic review and meta-
analysis. Addiction 108, 1562–1578 (2013). 
Scofield, M. D. et al. The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes 
Reflect the Importance of Glutamate Homeostasis. Pharmacol. Rev. 68, 816–871 (2016). 
Smyth, G. K. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in 
Microarray Experiments. Stat. Appl. Genet. Mol. Biol. 3, 1–25 (2004). 
 Su, Z. et al. A comprehensive assessment of RNA-seq accuracy, reproducibility and information 
content by the Sequencing Quality Control Consortium. Nat. Biotechnol. 32, 903–914 (2014). 
The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580–585 
(2013). 
 Waldmann, P., Mészáros, G., Gredler, B., Fuerst, C. & Sölkner, J. Evaluation of the lasso and the 
elastic net in genome-wide association studies. Front. Genet. 4, 1–11 (2013). 
 Xin, J. et al. High-performance web services for querying gene and variant annotation. Genome 
Biol. 17, 1–7 (2016). 
 Zhang, W. et al. Integrative transcriptome imputation reveals tissue-specific and shared 
biological mechanisms mediating susceptibility to complex traits. bioRxiv Prepr. 1–24 (2019). 
doi:https://dx.doi.org/10.1101/532929 
 Zou, H. & Hastie, T. Regularization and variable selection via the elastic net. J. R. Stat. Soc. Ser. B 
Stat. Methodol. 67, 301–320 (2005). 
 
  
39 
 
Appendix 
 
Arraystar AUD Cohort: Gene SNPS in Model Predicted R2 Pearson Correlation 
 ELAC2 7 0.323 0.697 
 SPSB2 22 0.418 0.691 
 SMYD4 38 0.139 0.643 
 LRRC37A 38 0.531 0.615 
 CNGA1 33 0.403 0.597 
 XRCC1 16 0.079 0.576 
 SNX31 23 0.287 0.568 
 ZNF626 23 0.056 0.559 
 ZNF880 50 0.712 0.554 
 HBS1L 65 0.146 0.528 
 LINC00667 19 0.339 0.527 
 DUS3L 16 0.328 0.522 
 POMZP3 60 0.581 0.520 
 L3HYPDH 48 0.385 0.502 
Table 8. Well predicted genes (Pearson correlation ≥ 0.50 between imputed and measured expression) 
for Arraystar alcohol use disorder cohort with recoding of missing SNPs.  
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Affymetrix AUD Cohort: Gene SNPS in Model Predicted R2 Pearson Correlation 
 GPNMB 13 0.308 0.775 
 LINC00339 21 0.521 0.766 
 SLC35F2 7 0.390 0.729 
 APIP 103 0.660 0.708 
 GSTM5 24 0.494 0.708 
 PILRB 56 0.591 0.677 
 NMRK1 54 0.497 0.674 
 KNOP1 49 0.498 0.656 
 ALDH8A1 71 0.330 0.646 
 TMEM80 33 0.328 0.629 
 GSTM3 49 0.241 0.625 
 SLC27A2 11 0.300 0.613 
 ERMAP 7 0.285 0.607 
 STAG3L4 24 0.495 0.604 
 TYW1 41 0.415 0.590 
 MTMR3 41 0.195 0.585 
 DHRS11 47 0.237 0.579 
 CHAF1A 42 0.278 0.573 
 HBS1L 65 0.146 0.573 
 C1GALT1 47 0.303 0.571 
 HPR 14 0.587 0.571 
 LIN7C 12 0.053 0.568 
 LXN 46 0.132 0.566 
 SNRPC 66 0.367 0.566 
 SPATA20 8 0.611 0.556 
 TCFL5 191 0.205 0.544 
 MED17 13 0.048 0.542 
 LARS2 41 0.298 0.539 
 RPS18 7 0.047 0.539 
 MARCH2 35 0.417 0.532 
 MTCH2 24 0.226 0.527 
 POLI 137 0.454 0.526 
 UROS 45 0.579 0.517 
 TRAPPC4 10 0.493 0.516 
 MFF 64 0.256 0.515 
 PMS2P3 40 0.160 0.513 
 LDAH 6 0.400 0.512 
 ST7L 17 0.053 0.512 
 PIGZ 81 0.392 0.510 
 XRCC1 16 0.079 0.508 
 TOR1B 18 0.064 0.504 
     
Table 9. Well predicted genes (Pearson correlation ≥ 0.50 between imputed and measured expression) 
for Affymetrix alcohol use disorder cohort.  
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Affymetrix Lung Cohort: Gene SNPS in Model Predicted R2 Pearson Correlation 
 CECR1 38 0.306 0.858 
 FAM118A 30 0.703 0.795 
 MARCH2 34 0.365 0.709 
 SLC7A9 45 0.267 0.708 
 PLD1 45 0.172 0.704 
 GSTT2 42 0.608 0.687 
 SNAPC1 13 0.108 0.685 
 TRIOBP 21 0.051 0.676 
 SAR1A 29 0.289 0.652 
 DHX8 44 0.019 0.651 
 ARSA 7 0.311 0.649 
 TFRC 42 0.036 0.636 
 POMT2 33 0.093 0.632 
 TMEM230 63 0.216 0.619 
 TIE1 22 0.111 0.614 
 CATSPERG 39 0.243 0.614 
 MOV10L1 22 0.016 0.605 
 CDIP1 17 0.084 0.600 
 TFIP11 68 0.015 0.598 
 GDPD3 20 0.074 0.591 
 PPIL2 34 0.276 0.585 
 MTMR3 27 0.165 0.583 
 MKRN2 61 0.088 0.577 
 CHMP2B 41 0.010 0.572 
 CPNE3 49 0.107 0.571 
 OXT 30 0.025 0.570 
 IL27RA 16 0.049 0.568 
 HSD17B7P2 20 0.102 0.564 
 SIRT4 21 0.079 0.557 
 ASB4 119 0.145 0.554 
 WAC 13 0.055 0.533 
 CECR5 32 0.015 0.532 
 TUBB4A 10 0.043 0.525 
 DAPP1 33 0.060 0.524 
 RBM6 52 0.439 0.523 
 EIF4B 17 0.111 0.522 
 CACNA1I 9 0.016 0.520 
 LIN7B 10 0.081 0.516 
 TTC19 34 0.149 0.514 
 GRAMD1A 28 0.120 0.502 
 CD22 36 0.251 0.501 
Table 10. Well predicted genes (Pearson correlation ≥ 0.50 between imputed and measured expression) 
for Affymetrix lung cohort.  
 
